The miss in both earnings per share (EPS) and sales compared to analyst estimates, along with a significant decrease from the previous year's figures, suggests a negative short-term impact on Zymeworks' stock price. The magnitude of the miss and the year-over-year decline in performance are likely to concern investors, potentially leading to decreased investor confidence and a drop in stock price.